Some U.S. biotech companies are considering moving early-stage trials of new medicines outside the United States as worry ...

The FDA did not respond to a request for comment. U.S. Health Secretary Robert F. Kennedy Jr. has said that the agency's ...

Revisions to classification criteria ‘will ensure homogeneous trial populations’ with data-driven scoring, a standardized MRI ...

The FDA and CDC recommended a pause for Ixchiq, a chikungunya vaccine, following reports of adverse events in recipients 60 ...

Cytokinetics' PDUFA date for aficamten was extended to December 26th of 2025, due to the FDA's need to review a submitted ...

Aurobindo Pharma's CuraTeQ Biologics receives marketing authorization for Zefylti filgrastim biosimilar in the UK and EU.

The United States is advising travellers aged 60 and up to hold off on getting the chikungunya vaccine while it looks into reports of possible side effects.

EMERYVILLE, Calif. , May 13, 2025 (GLOBE NEWSWIRE) -- XOMA Royalty Corporation (NASDAQ: XOMA), the biotech royalty aggregator ...

OLPRUVA: 5 new patient enrollment forms were received in Q1 2025, bringing the total from initial product availability in July 2023, and including Zevra's promotion of OLPRUVA since late January 2024, ...

AI-powered tools are enhancing precision, efficiency, and decision-making in biopharmaceutical development. Recently, Jared ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...